Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Liabilities and Shareholders Equity (2019 - 2025)

Benitec Biopharma's Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $79.1 million for Q4 2024.

  • For Q4 2024, Liabilities and Shareholders Equity rose 270.29% year-over-year to $79.1 million; the TTM value through Mar 2025 reached $131.3 million, up 148.3%, while the annual FY2024 figure was $52.2 million, 1069.58% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2024 was $79.1 million at Benitec Biopharma, up from $52.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $79.1 million in Q4 2024 and bottomed at $4.5 million in Q2 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $15.5 million (2020), against an average of $22.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity tumbled 72.06% in 2022 before it skyrocketed 1069.58% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $15.5 million in 2020, then dropped by 9.66% to $14.0 million in 2021, then increased by 29.26% to $18.1 million in 2022, then rose by 17.87% to $21.4 million in 2023, then soared by 270.29% to $79.1 million in 2024.
  • Per Business Quant, the three most recent readings for BNTC's Liabilities and Shareholders Equity are $79.1 million (Q4 2024), $52.2 million (Q2 2024), and $21.4 million (Q4 2023).